Neurocrine nears $2.5B-plus deal to buy Soleno Therapeutics - FT (NBIX:NASDAQ)

robot
Abstract generation in progress

Neurocrine Biosciences is reportedly in advanced talks to acquire Soleno Therapeutics for over $2.5 billion. The deal would value Soleno, known for its drug treating extreme hunger in Prader-Willi syndrome, in the low-to-mid $50s per share. This potential acquisition highlights Neurocrine’s expansion strategy in the biotech sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin